Therapeutic Function

Antiparkinsonian

Safety Profile

Poison by ingestion,subcutaneous, intraperitoneal, and intravenous routes.When heated to decomposition, it emits toxic fumes ofNOx.

Synthesis

Biperiden, 1-(5-norbornen-2-yl)-1-phenyl-3-piperidinopropan-1-ol (10.2.4), is also synthesized according to the method of making trihexyphenidyl, except by reacting 2-(1-piperidino)propiophenone (10.2.1) with 5-norbornen-2-ylmagnesiumbromide [33,34].

Definition

ChEBI: N-Propylpiperidine in which the methyl hydrogens are substituted by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all form of Parkinson's disease.

General Description

Biperiden,α-5-norbornen-2-yl- -phenyl-1-piperidinepropanol (Akineton), introduced in 1959,has a relatively weak visceral anticholinergic, but a strongnicotinolytic, action in terms of its ability to block nicotineinducedconvulsions. Therefore, its neurotropic action israther low on intestinal musculature and blood vessels. It hasa relatively strong musculotropic action, which is aboutequal to that of papaverine, in comparison with most syntheticanticholinergic drugs. Its action on the eye, althoughmydriatic, is much lower than that of atropine. These weakanticholinergic effects add to its usefulness in Parkinson syndromeby minimizing side effects.